ReviewOncogenesis2026
Imbalances of mitochondrial dynamics in solid tumors.
Review in Oncogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abtractIn cancer, mitochondrial fission and fusion dynamics are often imbalanced due to altered transcriptional and post-transcriptional control of their key regulators, resulting in either excessive fission or fusion. Despite being opposing processes, these imbalances in mitochondrial dynamics play a critical role in tumorigenic processes. Excessive fission drives metabolic reprogramming by promoting a shift toward aerobic glycolysis and regulating fatty acid metabolism, whereas excessive fusion supports oxidative phosphorylation and glutaminolysis. Both processes, in their own specific way, enable rapid growth and enhance survival in heterogeneous and unfavorable tumor microenvironments. Beyond metabolic regulation, excessive fission plays a key role in invasion and metastasis by promoting cytoskeletal remodeling for single-cell migration and inducing epithelial-to-mesenchymal transition. Moreover, both excessive fission and fusion can inhibit apoptosis and enhance therapy resistance by modulation of the intrinsic apoptosis pathway, upregulation of antioxidant defenses, and/or activation of autophagy. This review examines how both dysregulated fission and fusion contribute to tumorigenic processes in solid tumors and highlights mitochondrial dynamics as a promising therapeutic target.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.